🔎 Trials Near Me

Beranda › Limfoma Sel B Besar Difus › North Carolina

Uji klinis Limfoma Sel B Besar Difus di North Carolina

20 studi untuk Limfoma Sel B Besar Difus mencari peserta di lokasi di North Carolina.

Kota di North Carolina

Teks studi resmi (Bahasa Inggris)

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • University of North Carolina Medical Center ( Site 0136), Chapel Hill
  • Novant Health Presbyterian Medical Center ( Site 0177), Charlotte
  • Novant Health Forsyth Medical Center ( Site 0206), Winston-Salem
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06890884

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  • Duke University Medical Center, Durham
  • East Carolina University, Greenville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06091865

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  • East Carolina University ( Site 0159), Greenville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06717347

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Novant Health Cancer Institute- Hematology, Charlotte
  • Duke Blood Cancer Center, Durham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT06500273

A Study of ARC-02 in B-cell NHL

  • Levine Cancer Institute, Charlotte
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07691606

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Atrium Health Wake Forest Baptist, Winston-Salem
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05826535

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

  • Duke University Medical Center - Division of Hematologic Malignancies, Durham
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06116110

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Duke Cancer Institute, Durham
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Duke University Medical Center - Division of Hematologic Malignancies, Durham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  • Wake Forest University Health Sciences, Winston-Salem
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT06015880

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • Duke University Medical Center, Durham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT05131022

Registry of Older Patients With Cancer

  • Seby B. Jones Cancer Center, Boone
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
  • East Carolina University, Greenville
  • dan 4 lainnya
Menerima pesertaStudi observasional
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT01137825

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

  • Duke Univerisity, Durham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT04775745

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Atrium Health Cabarrus/LCI-Concord, Concord
  • Wake Forest University Health Sciences, Winston-Salem
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Feb 2026 · NCT05633615

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Menerima pesertaStudi observasional
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 27 Okt 2025 · NCT01137643

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University of North Carolina, Chapel Hill
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2025 · NCT05780034

A Study of NX-1607 in Adults With Advanced Malignancies

  • University of North Carolina, Chapel Hill
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2025 · NCT05107674

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Sep 2024 · NCT06238648

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  • Brody School of Medicine at East Carolina University, Greenville
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Apr 2023 · NCT04920617

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.